Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice

被引:67
作者
Crosby, Jeff R. [1 ]
Zhao, Chenguang [1 ]
Jiang, Chong [2 ]
Bai, Dong [1 ]
Katz, Melanie [1 ]
Greenlee, Sarah [1 ]
Kawabe, Hiroshi [3 ]
McCaleb, Michael [1 ]
Rotin, Daniela [2 ]
Guo, Shuling [1 ]
Monia, Brett P. [1 ]
机构
[1] Ionis Pharmaceut, 2855 Gazelle Court, Carlsbad, CA 92010 USA
[2] Hosp Sick Children, 686 Bay St, Toronto, ON M5G 0A4, Canada
[3] Max Planck Inst Expt Med, Gottingen, Germany
关键词
Cystic fibrosis; ENaC; Antisense oligonucleotide; Aerosol; EPITHELIAL NA+ CHANNEL; SODIUM-CHANNELS; MOLECULAR-BASIS; ALLERGIC MICE; CFTR; INHALATION; AMILORIDE; MOUSE; GENE; IDENTIFICATION;
D O I
10.1016/j.jcf.2017.05.003
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Epithelial sodium channel (ENaC, Scnnl) hyperactivity in the lung leads to airway surface dehydration and mucus accumulation in cystic fibrosis (CF) patients and in mice with CF-like lung disease. Methods: We identified several potent ENaC specific antisense oligonucleotides (ASOs) and tested them by inhalation in mouse models of CF-like lung disease: Results: The inhaled ASOs distributed into lung airway epithelial cells and decreased ENaC expression by inducing RNase H1-dependent degradation of the targeted Scnnla mRNA. Aerosol delivered ENaC ASO down-regulated mucus marker expression and ameliorated goblet cell metaplasia, inflammation, and airway hyper-responsiveness. Lack of systemic activity of ASOs delivered via the aerosol route ensures the safety of this approach. Conclusions: Our results demonstrate that antisense inhibition of ENaC in airway epithelial cells could be an effective and safe approach for the prevention and reversal of lung symptoms in CF and potentially other inflammatory diseases of the lung. (c) 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:671 / 680
页数:10
相关论文
共 38 条
  • [1] DEMONSTRATION THAT CFTR IS A CHLORIDE CHANNEL BY ALTERATION OF ITS ANION SELECTIVITY
    ANDERSON, MP
    GREGORY, RJ
    THOMPSON, S
    SOUZA, DW
    PAUL, S
    MULLIGAN, RC
    SMITH, AE
    WELSH, MJ
    [J]. SCIENCE, 1991, 253 (5016) : 202 - 205
  • [2] 2'-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells
    Baker, BF
    Lot, SS
    Condon, TP
    ChengFlournoy, S
    Lesnik, EA
    Sasmor, HM
    Bennett, CF
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (18) : 11994 - 12000
  • [3] RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
    Bennett, C. Frank
    Swayze, Eric E.
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2010, 50 : 259 - 293
  • [4] Mechanisms of ENaC regulation and clinical implications
    Bhalla, Vivek
    Hallows, Kenneth R.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 19 (10): : 1845 - 1854
  • [5] Respiratory distress and perinatal lethality in Nedd4-2-deficient mice
    Boase, Natasha A.
    Rychkov, Grigori Y.
    Townley, Scott L.
    Dinudom, Anuwat
    Candi, Eleanora
    Voss, Anne K.
    Tsoutsman, Tatiana
    Semsarian, Chris
    Melino, Gerry
    Koentgen, Frank
    Cook, David I.
    Kumar, Sharad
    [J]. NATURE COMMUNICATIONS, 2011, 2
  • [6] Future trends in cystic fibrosis demography in 34 European countries
    Burgel, Pierre-Regis
    Bellis, Gil
    Olesen, Hanne V.
    Viviani, Laura
    Zolin, Anna
    Blasi, Francesco
    Elborn, J. Stuart
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (01) : 133 - 141
  • [7] AMILORIDE-SENSITIVE EPITHELIAL NA+ CHANNEL IS MADE OF 3 HOMOLOGOUS SUBUNITS
    CANESSA, CM
    SCHILD, L
    BUELL, G
    THORENS, B
    GAUTSCHI, I
    HORISBERGER, JD
    ROSSIER, BC
    [J]. NATURE, 1994, 367 (6462) : 463 - 467
  • [8] Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
    Clancy, J. P.
    Rowe, Steven M.
    Accurso, Frank J.
    Aitken, Moira L.
    Amin, Raouf S.
    Ashlock, Melissa A.
    Ballmann, Manfred
    Boyle, Michael P.
    Bronsveld, Inez
    Campbell, Preston W.
    De Boeck, Kris
    Donaldson, Scott H.
    Dorkin, Henry L.
    Dunitz, Jordan M.
    Durie, Peter R.
    Jain, Manu
    Leonard, Anissa
    Mccoy, Karen S.
    Moss, Richard B.
    Pilewski, Joseph M.
    Rosenbluth, Daniel B.
    Rubenstein, Ronald C.
    Schechter, Michael S.
    Botfield, Martyn
    Ordonez, Claudia L.
    Spencer-Green, George T.
    Vernillet, Laurent
    Wisseh, Steve
    Yen, Karl
    Konstan, Michael W.
    [J]. THORAX, 2012, 67 (01) : 12 - 18
  • [9] Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis
    Clark, Kenneth L.
    Hughes, Stephen A.
    Bulsara, Pallav
    Coates, Jill
    Moores, Kitty
    Parry, Joel
    Carr, Michael
    Mayer, Ruth J.
    Wilson, Paul
    Gruenloh, Chris
    Levin, Daren
    Darton, Jill
    Weber, Wolf-Michael
    Sobczak, Katja
    Gill, Deborah R.
    Hyde, Stephen C.
    Davies, Lee A.
    Pringle, Ian A.
    Sumner-Jones, Stephanie G.
    Jadhav, Vasant
    Jamison, Sharon
    Strapps, Walter R.
    Pickering, Victoria
    Edbrooke, Mark R.
    [J]. MOLECULAR THERAPY-NUCLEIC ACIDS, 2013, 2 : e65
  • [10] DEFECTIVE EPITHELIAL CHLORIDE TRANSPORT IN A GENE-TARGETED MOUSE MODEL OF CYSTIC-FIBROSIS
    CLARKE, LL
    GRUBB, BR
    GABRIEL, SE
    SMITHIES, O
    KOLLER, BH
    BOUCHER, RC
    [J]. SCIENCE, 1992, 257 (5073) : 1125 - 1128